https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-kidney-cancer-renal-cell-cancer-likelihood-of-approval/
Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Kidney Cancer (Renal Cell Cancer).
bristol myers squibbkidney cancersitravatinibmalaterenal
https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-epithelial-ovarian-cancer-likelihood-of-approval/
Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Epithelial Ovarian Cancer.
bristol myers squibbepithelial ovarian cancersitravatinibmalate